Introduction Atherosclerosis
The term, atherosclerosis, as it was originally coined by Thoma in 1886, was devised to describe a degenerative process involving the progressive hardening of the blood vessel wall. 1 Today we have advanced to the understanding that the ultimate atherosclerotic lesion is a complex and heterogeneous arrangement of rapidly proliferating and migrating cells that produce and support an active connective tissue matrix. Two major forms of atherosclerotic lesions have been described: the fatty streak and the fibrous plaque. Classic fatty streaks are raised, narrow, yellowed lesions that extend in the direction of blood flow. They are nonobstructive and are likely, but yet unproven, precursors of more advanced lesions. The streaks are characterized by subendothelial collections of foam cells, smooth muscle cells (SMC), T-lymphocytes, and an extracellular matrix of lipid, collagen, elastin, and proteoglycan.
2 -3 - 4 Monoclonal antibody studies have shown that foam cells are primarily monocyte-derived macrophages and occasionally SMC that have imbibed cholesterol and cholesterol esters. 5 The fundamental and characteristic lesion of advanced atherosclerosis is the fibrous plaque. The histobgical composition of this lesion is variable but typically consists of a necrotic core of cellular debris, lipid, cholesterol, and calcium deposits overlain by SMC, macrophages, and T-lymphocytes, all of which are capped by a layer of fibrous tissue that is composed of SMC, leukocytes, and a dense connective tissue matrix. 8 Larger plaques are surrounded by a vasa vasorum that rises from the adventitia. 7 As disease advances, plaque may undergo further degeneration, including calcification, ulceration, and necrosis. Such complicated lesions are prone to intramural hemor-rhage, rupture, and superimposed thrombosis that may play roles in end-organ disease such as myocardial infarction. 8 
Pathogenesis of Atherosclerosis
Several theories explaining the pathogenesis of atherosclerosis based on an analysis of animal models and human atherosclerotic disease have been proposed (for reviews, see references 9 to 14). In the original responseto-injury model of Ross and Glomset, injury to, and subsequent denudation of, the endothelium was felt to be responsible for platelet adhesion and aggregation. 910 It was suggested that growth factors released from the platelets were responsible for the migration and proliferation of SMC into the intima where these growth factors could accumulate and secrete components of an extracellular matrix. Modifications of this model were developed when endothelial denudation and platelet adhesion were found to be neither necessary nor sufficient to cause atherosclerotic lesions. 141518 In particular, an important role for monocytes and macrophages in the pathogenesis of atherosclerosis was proposed because of the similarity of this process to the classic inflammatory response. 12 - 14 ' 15 ' 17 Another theory suggested that the pathogenesis of atherosclerosis was due to the monoclonal proliferation of SMC that arose as the result of a mutagenic effect in a stem cell.
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Growth Factors
Common to these theories is the concept that a number of synchronized events, including adhesion, migration, proliferation, and transformation of cells, occur in order for atherosclerotic plaques to develop. It Is widely recognized that growth factors mediate these events and, therefore, it is postulated that they play an important role in the pathogenesis of atherosclerosis. Table 1 lists some of the growth factors produced by four cell types, which are thought to play a role in atherosclerosis: platelets, monocytes-macrophages, endothelial cells, and SMC. The platelet-derived growth factor (PDGF) is a stimulator of monocyte and SMC migration as well as being a potent SMC mitogen.
19 -22 It has been suggested that PDGF released from platelets during thrombosis is responsible for stimulating SMC migration into the intima and for subsequent SMC proliferation. 12 Plus Indicates growth factor production. Blank indicates no known growth factor production.
PDGF=platelet-derived growth factor, FGF=flbroblast growth factor, TGF-alpha=transforming growth factor-alpha, TGFbeta=transforming growth factor-beta, EGF=epidermal growth factor.
paracrine mechanisms where degranulated platelets, infiltrating macrophages, and damaged or activated endothelial cells release PDGF that, in turn, stimulates SMC migration and proliferation In the intima. Alternatively, since SMC themselves synthesize PDGF, autocrinestimulated growth of SMC might be, in part, responsible for the development of monoclonal atherosclerotic lesions.
14 '
18
PDGF mRNA transcripts have been found In normal arteries where cell turnover is low, as well as in human atherosclerotic plaques. Thus, PDGF gene expression alone does not appear to explain the proliferative events in atherosclerosis. 31 However, the cell types associated with atherosclerotic lesions synthesize other growth factors besides PDGF. Platelets contain transforming growth factor-beta (TGF-beta), epidermal growth factor (EGF), as well as potent endothelial cell growth factors.
32 -35 Macrophages synthesize transforming growth factor-alpha (TGFalpha), fibroblast growth factor (FGF), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), 36 -40 as well as yet-uncharacterized growth factors. 23 Endothelial cells synthesize FGF and TGF-beta 284142 and heparin-like molecules that are inhibitors of SMC proliferation.
43 SMC synthesize FGF. 44 Thus, the chemotactjc and proliferative events characteristic of atherosclerosis may be regulated by the production of multiple growth factors by the cells associated with atherosclerosis plaque formation.
In this article, we review the biochemical and biological properties of FGF and consider the possible role of FGF In the pathogenesis of atherosclerosis. FGF has a number of biological properties comparable to PDGF. For example, FGF is a potent SMC mltogen 4446 and is synthesized by three cell types associated with atherosclerosis: endothelial cells, 284146 macrophages, 37 and SMC. 44 FGF also has properties not shared by PDGF, including the ability to stimulate endothelial cell growth and angbgenesis. 47 These properties may be important since endothelial cell proliferation occurs in rabbits with hypercholesterolemia, 48 and vascularization of the blood vessel wall is necessary to maintain the atherosclerotic plaque. 7 On the other hand, the ability of FGF to stimulate endothelial ceil proliferation may lead to the repair of endothelium and to protection against atherosclerosis. Another property of FGF that is not shared by PDGF is that it is associated with endothelial cells and with basement membranes produced by endothelial cells. 28414649 Thus, FGF might be released after injury to endothelium and become available. Given these properties of FGF, one could speculate that FGF, as well as PDGF, is a possible candidate for mediating the cellular events that lead to the formation of atherosclerotic lesions, whether these lesions arise as a response to injury as part of an inflammatory mechanism or by autocrine growth of SMC.
Biochemical Properties of Fibroblast Growth Factors Isolation and Purification
The term, fibroblast growth factor, was first used to describe a cationic polypeptJde isolated from pituitary and brain that stimulated cell division in 3T3 cells. 5051 Purified pituitary basic FGF (bFGF) is a polypeptide with a molecular weight of 16 000 to 18 000 and a pi of Q.6. 52 Brain was found to contain another species of FGF, which was anionic in nature.
535455 Purified brain acidic FGF (aFGF) is a polypeptide with a molecular weight of about 16 000 and a pi of 5.
M Although originally described as mltogens for fibroblasts, both bFGF and aFGF were found to be potent mitogens for other cells, in particular endothelial cells. 4755 '
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Heparln Affinity
The characterization and purification of FGFs were greatly facilitated by the discovery that these polypeptldes have a strong affinity for the anionic glycosaminoglycan, heparin. Extracts of chondrosarcoma, 58 cartilage, 59 hypothalamus, 80 and hepatoma cells 61 were found to contain a cationic polypeptide mitogenic for 3T3 and endothelial cells that adhered tightly to a column of heparinSepharose and could be eluted with 1.5 M NaCI. Subsequently, these cationic heparin-binding growth factors were identified as species of bFGF. Anionic heparinbinding growth factors eluting with 1 M NaCI were found in extracts of brain, 62 -* 5 hypothalamus, 60 retina, 86 and eye. 67 These anionic heparin-binding growth factors were subsequently identified as species of aFGF. It is now recognized that over 20 different growth factors that had been isolated from a variety of tissues and given different names are actually either bFGF or aFGF, and that heparin affinity chromatography is an essential step for the characterization and purification of both types of FGF. 58 - 69 The affinity of FGF for heparin might reflect an association that occurs in cells and tissues. bFGF is bound to heparin-like molecules, probably heparan sulfate proteoglycan, in subendotheiial cell extracellular matrix 4870 and in basement membrane. 49 Another important property of heparin, as well as heparan sulfate, is that they protect FGF from denaturation and degradation. 7172 Thus, heparin-like molecules might serve to protect and stabilize FGF in vivo.
Determination of the true molecular weights of bFGF and aFGF have been complicated by the susceptibility of these polypeptides to protease-mediated truncations that occur mostly at the amino terminus, but which have no adverse affect on biological activity. 4578 - 80 However, structural analysis of the various FGF polypeptkje species, along with analysis of FGF cDNA open reading frames, has clarified the situation. When first sequenced, bFGF was reported to be a 146 amino acid polypeptide. 81 However, a 154 amino acid of bFGF extended at the amino terminus by eight amino acids was isolated from pituitary and brain when purification was done in the presence of protease inhibitors.
7879 A 154 amino acid form of bFGF is consistent with the open reading frame of bFGF cDNA 82 and probably represents the intact form of bFGF. On the other hand, recent evidence suggests that there may be species of bFGF containing more than 154 amino acids. A 157 amino acid form of bFGF extended at the amino terminus has been isolated from placenta, 74 and a 163 amino acid form of basic FGF extended at the amino terminus has been found in human hepatoma cells (Klagsbrun and Smith, unpublished results). In addition, 22 000 to 25 000 molecular weight forms of bFGF have been isolated from guinea pig and rat brain 8384 and from rodent cells (Klagsbrun et al., unpublished observations). Whether these higher molecular forms represent precursors, alternative splicing mechanisms, or the existence of alternative initiation sites is yet to be determined.
aFGF was originally described as a 140 amino acid polypeptide, 738586 but protein sequence 80 and cDNA 87 analysis suggest that aFGF is a 154 amino acid polypeptide, as is bFGF. The 154 amino acid form of aFGF is also known as beta-endothelial cell growth factor (beta-ECGF).
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Genes
The availability of bFGF and aFGF primary amino acid sequences has resulted in the cloning of bFGF and aFGF genes. A bovine cDNA clone encoding bFGF was isolated from a bovine pituitary cDNA library, and the nucleotide sequence was determined. 82 Subsequently, the bFGF gene was also cloned from human libraries 74888990 and was mapped to chromosome 4. 90 abFGF mRNA transcripts of 7.0 kilobase (kb) and 3.7 kb were found in hypothalamus, hepatoma cells, and endothelial cells.
4182
The predicted amino acid sequence of the open reading frame corresponds to that of a 154 amino acid potypeptide. No consensus signal peptide sequence has been found, suggesting that bFGF is not a secreted protein.
A human cDNA clone encoding ECGF/aFGF was isolated from a human brain stem cDNA library, and its nucleotide sequence was determined. 87 Southern blot analysis suggested that there was a single ECGF/aFGF gene that mapped to human chromosome 5. The size of the human brain stem ECGF/aFGF mRNA transcript is 4.8 kb.
FGF cDNA has been expressed in E. coH 60 and in mammalian cell lines. 91 - 84 Mammalian cells transfected with bFGF and aFGF genes are partially transformed in culture; they acquire properties such as lowered serum requirement, growth to higher saturation density, and growth in agar. However, if cells are transfected with a bFGF cDNA to which an immunogtobulin heavy chain signal peptide is attached upstream, the cells form rapidly growing tumors within 2 weeks in syngeneic animals. 91 Thus, bFGF, when altered by addition of a signal peptide, is a transforming protein that stimulates cell growth in an autocrine manner. The oncogenic potential of bFGF is of interest in light of the discoveries that there are at least three oncogenes that encode for proteins and that have a 40% to 50% homology for bFGF and aFGF. The first FGF homologue to be described was int-2, which is a product of integration of mammary tumor virus into the host genome. 95 The hst oncogene was isolated from a human stomach tumor. 9697 The same oncogene was later isolated from Kaposi's tumor and was named KFGF. 98 A third oncogene, FGF-5, was isolated from a human bladder tumor. 99 KFGF has been recently shown to be glycosylated and secreted as a mature protein of 176 amino acids. 100 PDGF is the product of the c-sis proto-oncogene and has transforming potential in transformed cells. The ability of FGF and FGF homologues to be transforming proteins that stimulate autocrine growth might be relevant when considering the hypothesis that atherosclerosis may arise by autocrine growth of monoclonally derived SMC synthesizing their own PDGF or FGF.
Receptors
High affinity receptors for FGF with molecular weights of 125 000 to 165 000 and K d values of about 10" 11 have been identified on numerous cell types. 101 - 107 It appears that bFGF and aFGF have the same receptor. 103106 In addition, low affinity receptors for bFGF with a K<j of about 2x10~9 have been identified. 108 These low affinity receptors appear to be heparin-like molecules that may act to concentrate bFGF on cell surfaces and to facilitate access to high affinity receptors. The existence of FGF receptors on vascular endothelial cells and SMC makes the consideration of FGF as a putative factor in atherogenesis all the more plausible.
Biological Properties of Flbroblast Growth Factors Tissue Sources
FGF is widely distributed.
47109110 aFGF is found mainly in neural tissue such as brain, hypothalamus, retina, and eye, but also in bone. bFGF appears to be more ubiquitous and is found in neural tissue such as brain, pituitary, hypothalamus, and eye; in skeletal tissue such as cartilage and bone; in reproductive tissue such as placenta, corpus luteum, testis, ovary, and prostate; in glands such as adrenal cortex; in organs such as kidney, heart, and liver; in white blood cells such as macrophages; and in tumors such as chondrosarcoma, hepatoma, and melanoma. In fact, it appears that FGFs may be one of the most widely distributed growth factors in the body. The ubiquity of FGF in tissues that are neither growing nor undergoing angiogenesis suggests that the activity of these growth factors must be highly regulated under normal physiological conditions. 119 Only IL-1 appears to share with bFGF the property of being cell associated.
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Extracellular Matrix and Basement Membrane
bFGF synthesized by endotheiiai cells is associated not only with these cells but also with the subendothelial cell extracellular matrix. 4670 In the cornea, bFGF is mostly associated with Descemet's membrane, a basement membrane produced by corneal endotheiiai cells.
49 bFGF can be released from extracellular matrix and basement membrane by displacement with heparin or by degradation with heparinases and heparanases. 484970121 The association of bFGF with cells, extracellular matrix, and basement membrane has led to the speculation that bFGF may be a "stored" growth factor. Storage of bFGF in such a way that it has no access to its receptors may be a mechanism to regulate the activity of this potent mitogen, which appears to be ubiquitous. It is further speculated that after injury, bFGF is released by heparanases and proteases that degrade extracellular matrix and basement membrane. Inflammatory cells such as macrophages produce these enzymes.
Release of stored FGF might be relevant to the pathogenesis of atherosclerosis. Release of FGF from subendothelial extracellular matrix could occur as a result of injury to the endothelium or the enzymatic activity of infiltrating macrophages.
Mltogenesls, Chemotaxls, and Differentiation
FGF is a multipotential factor active in nanogram quantities. Both bFGF and aFGF are potent mitogens in vitro, active in the 0.1 to 1 ng/ml range. They stimulate the proliferation of a variety of cells including fibroblasts, corneal endotheiiai cells, vascular endotheiiai cells, vascular SMC, granulosa cells, chondrocytes, osteoblasts, myoblasts, glial cells, and rat neuronal precursor celis.45,47.69,109,122.123 FGF is also a chemotactic factor, for example, for endotheiiai cells, fibroblasts, and astroglial cells.
124125126 Heparin might play a role in FGF-induced mitogenesis. In the presence of heparin, the activity of aFGF in stimulating endotheiiai cell proliferation is 100-fold. 127 It is not clear what the role of heparin is in potentiating FGF activity. The effect might be on the growth factor itself, since it has been shown that heparin and heparan sulfate protect FGF against denaturation and degradation. 7172 On the other hand, the effect might be on the FGF receptor, since heparin has been shown to decrease the K<j of FGF binding. 128 
FGF appears to regulate the differentiation of neuronal cells. It stimulates neurtte outgrowth in PC12cells
129130 ' 131 and in hippocampal neurons. 132 In addition, FGF prolongs the survival in culture of hippocampal neurons, 132 lesioned cholinergic neurons, 133 and cerebral cortical neurons. 134 The mitogenic, chemotactic, and differentiating properties of FGF suggest that this growth factor may play an important role in embryonic development. bFGF acts as a morphogen by inducing mesodenm formation in the 1024 to 2048 cell stage of frog embryos. 135 The natural ventrovegetal signal in the frog embryo is blocked by heparin, suggesting that it may be a heparin-binding growth factor such as FGF. In addition, xenopus oocytes and early embryos have an appreciable store of what appears to be FGF mRNA. 136 The effect of FGF on mesodenm induction is greatly enhanced by TGF-beta. Together they induce muscle actin mRNA to levels comparable to those found in the intact embryo. 138 These results suggest that bFGF and TGF-beta acting in concert are responsible for inducing mesoderm in embryonic development. 138 '
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Anglogenesls
Both bFGF and aFGF are angiogenic factors.
47109138
Angiogenesis is a complex process involving the degradation of capillary basement membrane, the migration and proliferation of endotheiiai cells, and tube formation. FGF can stimulate all of these processes in vitro. For example, bFGF is mitogenic and chemotactic for endotheiiai cells, stimulates the production by endotheiiai cells of collagenase and plasminogen activator, (proteases capable of degrading basement membrane 124 ), and induces capillary endotheiiai cells to migrate into threedimensional collagen matrices to form capillary-like tubes. 139 Both bFGF and aFGF, at levels of 10 to 100 ng, are angiogenic in vivo in the chick chorioallantoic membrane and cornea bioassays. 47138 bFGF has been shown to be active in inducing the migration of vascular granulation tissue containing highly dilated blood vessels into polyvinyl sponges that are implanted into rats. 140 aFGF complexed to gelatin induces angiogenesis in the neck and peritoneal cavities of the rat. 141 Stimulation of angiogenesis might be relevant for atherosclerosis since it has been shown that vasa vasoaim Is necessary for the continued growth of atherosclerotic plaque. 
Fibroblast Growth Factors and the Pathogenesls of Atherosclerosis-a Proposal
The SMC proliferation characteristic of atherosclerosis may be the result of a number of processes including the mitogenic effects of growth factors. In considering growth factors as being part of the etiology of atherosclerosis, most of the attention has been focused on PDGF. The potential involvement of PDGF stems from its being a potent smooth muscle mitogen and from its secretion by the cells deemed vital to the initiation and propagation of the atherosclerotic lesion. However, PDGF alone cannot explain all of the proliferative events that occur in atherosclerosis. 31 The same cells that produce PDGF produce other growth factors as well (Table 1) . Of these growth factors, FGF, in particular, has certain biological properties that make it a candidate to be considered when postulating a theory of atherogenesis that involves growth factors. The salient properties of FGF to be considered in such a theory are as follows: 1) Three of the cell types thought to be associated wtth the atherosclerotic process: endothelial cells, 2 8 4 1 4 8 macrophages, 37 and SMC 44 synthesize FGF. 2) FGF is an SMC mitogen. 4445 Thus, FGF could be partly responsible for the migration of SMC into the intima and their subsequent proliferation.
3) FGF is an endothelial cell mitogen 47138 and might be responsible for the endothelial cell turnover found when atherosclerosis Is induced. 48 However, endothelial cell proliferation might also lead to repair of endothelium and, consequently, delay development of the atherosclerotic lesion. 4) FGF is an angiogenesis factor. 47138 ' 140 . 141 Vasa vasorum derived from adventitia may be necessary to provide nutrients for atherosclerotic plaques. Development of vasa vasorum might be regulated by angiogenesis factors such as FGF.
5) Endothelial cell-derived bFGF is associated with endothelial cells, subendothelial cell extracellular matrix, and basement membrane. 28484970 The denudation of endothelium and the exposure of underlying subendothelial ECM that has been observed in animal models of atherosclerosis could lead to the release of "stored" bFGF, which would then be available for stimulating SMC proliferation in the neighboring intima. Thus, a role for FGF would be consistent with the response to injury model. 910 On the other hand, the available FGF might repair damaged endothelium, in effect preventing platelet Abbreviations are explained in the footnote to Table 1 .
• 
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A question mark at the end of an arrow for TGF-alpha (TGF-a) Indicates that the effects of this growth factor on endothelial and smooth muscle cells Is uncertain.
adhesion and thereby protecting against the propagation of atherosclerosis. 6) Consistent with the hypothesis that atherosclerotic lesions arise from the action of inflammatory cells, macrophage-derived FGF 37 might be the stimulant for SMC proliferation.
7) SMC-derived FGF might stimulate cell proliferation in an autocrine manner consistent with the hypothesis that atherosclerosis arises from the proliferation of monoclonal populations of SMC. 18 The finding 91 that bFGF, when altered by addition of a signal peptide, acts as an oncogene leading to unrestricted cell growth is consistent with such a hypothesis.
Based on these observations, we have proposed a potential role for FGF and other growth factors in the pathogenesis of atherosclerosis (Figure 1) . A schematic cross-section of an artery containing an atherosclerotic plaque and depicting the postulated interactions of platelets, macrophages, endothelial cells, and SMC in the pathogenesis of atherosclerosis is shown in Figure 1 . These cells synthesize growth factors such as FGF, PDGF, TGF-beta, TGF-alpha, and EGF (Table 1) , which have differing effects on the proliferation of endothelial cells and SMC (Table 2) .
A model for potential autocrine and paracrine growth factor mechanisms that may be associated with atherosclerosis is illustrated schematically in Figure 2 . This model is based on the following observations that are made when growth factors are added to cultured cells (Table 2 ): 1) FGF is mitogenic for endothelial and SMC. 444547 2) PDGF is mitogenic for smooth muscle, but not endothelial, cells. 142 3) TGF-beta is an inhibitor of endothelial cell proliferation 143144146 although it is an angiogenesis factor. 146 The effect of TGF-beta on SMC proliferation is unclear since TGF-beta has been shown to both inhibit 147148 and potentiate 148 the growth of aortic SMC. 4) EGF is mitogenic for SMC. 148 The effects of EGF on endothelial cell proliferation is unclear. It has been reported by one group, 150 but not by ourselves (unpublished observations), that EGF is an endothelial cell mitogen. 5) There is not much data on the effects of TGF-alpha on smooth muscle and endothelial cells. In this model, the platelet and macrophage-derived growth factors are potential paracrine factors, while the endothelial cell and smooth muscle-derived growth factors could act by both paracrine and autocrine mechanisms. The autocrine pathways could occur either via external loops or via internal loops, as has been shown for both FGF and PDGF. 91 '
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The inclusion of growth factors other than PDGF in a model for growth factor-mediated atherogenesis provides a scheme for intercellular and intracellular regulation, if PDGF were the only growth factor involved, then one might expect unimpeded smooth muscle cell proliferation leading to rapid occlusion of the blood vessel lumen. Yet, atherogenesis is a modulated event in which continuous remodeling of vascular lesions occur. These events might be mediated by other growth factors. For example, FGF could re-endothelialize the blood vessel after injury. Newly repaired endothelium could then inhibit further SMC proliferation by producing inhibitors such as the heparin-like inhibitor of SMC growth 43 and TGF-beta. 147 Thus, the development of atherosclerotic lesions could be tempered by the presence of other growth factors and growth inhibitors that try to re-establish normal hemostasis.
In assessing this model, one must remember that it is oversimplified and considers only the known growth factors and their effects in cell culture. Moreover, it is not certain that growth factor production by cells in vivo approximates those found in vitro. For example, cultured endothelial cells produce far more PDGF than do endothelial cells in a blood vessel. 152 In addition, the interactions of growth factors and cells might be highly complex since growth factors are capable of inducing the synthesis of other growth factors. For example, TGF-beta stimulates transcription of PDGF A and B chains in renal microvascular endothelial cells. 153 Finally, while macrophages, platelets, endothelial cells, and smooth muscle are all capable of synthesizing growth factors, it is necessary to determine in the pathogenesis of atherosclerosis which of these cells are the active producers and under what conditions. Because of its ability to produce so many different growth factors, 154 the macrophage may play a partJcularty important role. In summary, a clear understanding of the role of growth factors in atherogenesis is still in its early stages. However, it is important to consider a role for FGF in this process because this growth factor appears to be intimately associated with the vascular system. 
